Entera Bio appointed Laura Hamill as a Class I director effective December 1, 2026. Hamill brings over 35 years of commercial leadership experience from Gilead Sciences and Amgen. She joins the audit and corporate governance committees. Yonatan Malca is stepping down from the Board on the same date to succeed him. Entera develops oral peptide therapies for conditions including osteoporosis.
